Activities per year
- 1 - 50 out of 78 results
Search results
-
Differential induction of micronuclei in peripheral lymphocytes and exfoliated urothelial cells of workers exposed to 4,4’-methylenebis-(2-chloroaniline)(MOCA) and bitumen fumes
Erin Morton (Speaker) & J W Edwards (Speaker)
2001Activity: Talk or presentation types › Oral presentation
-
The Clinical Pharmacology of Methadone Induction
Erin Morton (Speaker), A Somogyi (Speaker), F Bochner (Speaker) & J. M. WHITE (Speaker)
2004Activity: Talk or presentation types › Oral presentation
-
Differential induction of micronuclei in peripheral lymphocytes and exfoliated urothelial cells of workers exposed to 4,4’-methylenebis-(2-chloroaniline)(MOCA) and bitumen fumes. Murray, E.B. and Edwards, J.W. (2005). Reviews on Environmental Health 20(3): 163-176. 10.1515/REVEH.2005.20.3.163
Erin Morton (Other)
2005Activity: Other activity types › Other
-
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L. Am Heart J. 2010 Oct;160(4):655-61. doi: 10.1016/j.ahj.2010.07.006. PMID: 20934559 Clinical Trial.
Erin Morton (Other)
2010Activity: Other activity types › Other
-
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13. PMID: 22077816 Clinical Trial.
Erin Morton (Other)
2012Activity: Other activity types › Other
-
Vorapaxar expands antiplatelet options. Duerschmied D, Bode C. Hamostaseologie. 2012;32(3):221-227. doi: 10.5482/HAMO-12-05-0006. Epub 2017 Dec 28. PMID: 29589363 English.
Erin Morton (Other)
2012Activity: Other activity types › Other
-
Utility of Lp-PLA2 in lipid-lowering therapy. Racherla S, Arora R. Am J Ther. 2012 Mar;19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32. PMID: 20634673 Review.
Erin Morton (Other)
2012Activity: Other activity types › Other
-
Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors. Wang K, Xu W, Zhang W, Mo M, Wang Y, Shen J. Bioorg Med Chem Lett. 2013 May 15;23(10):2897-901. doi: 10.1016/j.bmcl.2013.03.062. Epub 2013 Mar 26. PMID: 23575276
Erin Morton (Other)
2013Activity: Other activity types › Other
-
To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. Marathe GK, Pandit C, Lakshmikanth CL, Chaithra VH, Jacob SP, D'Souza CJ. J Lipid Res. 2014 Sep;55(9):1847-54. doi: 10.1194/jlr.R045492. Epub 2014 May 23. PMID: 24859738. Review.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Am J Cardiol. 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard.2014.05.054. Epub 2014 Jun 18. PMID: 25129064 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, Moliterno DJ, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW. Am Heart J. 2014 Dec;168(6):869-77.e1. doi: 10.1016/j.ahj.2014.09.002. Epub 2014 Sep 16. PMID: 25458650 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9. PMID: 24402559 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW. Am Heart J. 2014 Oct;168(4):588-96. doi: 10.1016/j.ahj.2014.06.017. Epub 2014 Jul 4. PMID: 25262270 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Coronary artery disease: Darapladib fails to improve the STABILITY of CAD. Roberts A. Nat Rev Cardiol. 2014 Jun;11(6):310. doi: 10.1038/nrcardio.2014.50. Epub 2014 Apr 15. PMID: 24736761
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW. J Am Heart Assoc. 2014 Jul 10;3(4):e001032. doi: 10.1161/JAHA.114.001032. PMID: 25012288. Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Am J Cardiol. 2014 Mar 15;113(6):936-44. doi: 10.1016/j.amjcard.2013.11.052. Epub 2013 Dec 25. PMID: 24444781 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW. J Am Coll Cardiol. 2014 Mar 25;63(11):1048-57. doi: 10.1016/j.jacc.2013.10.048. Epub 2013 Nov 21. PMID: 24211500 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. J Thromb Thrombolysis. 2014 Nov;38(4):423-9. doi: 10.1007/s11239-014-1075-4. PMID: 24676931 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, Moliterno DJ, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW. Eur Heart J Acute Cardiovasc Care. 2014 Sep;3(3):246-56. doi: 10.1177/2048872614527838. Epub 2014 Mar 13. PMID: 24627331 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
Darapladib for preventing ischemic events in stable coronary heart disease. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30. PMID: 24678955 Clinical Trial.
Erin Morton (Other)
2014Activity: Other activity types › Other
-
STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Hassan M. Glob Cardiol Sci Pract. 2015 Jan 26;2015:6. doi: 10.5339/gcsp.2015.6. eCollection 2015. PMID: 25830150.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. PMID: 26052984 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. Serebruany VL, Choi SY, Kim MH. Int J Cardiol. 2016 Feb 15;205:13-16. doi: 10.1016/j.ijcard.2015.12.001. Epub 2015 Dec 3. PMID: 26709134
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW. J Am Heart Assoc. 2015 Dec 15;4(12):e002546. doi: 10.1161/JAHA.115.002546. PMID: 26672080 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Am J Cardiol. 2015 May 15;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043. Epub 2015 Feb 18. PMID: 25776457 Clinical Trial.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Redesigning TRACER trial after TRITON. Serebruany VL. Int J Cardiol. 2015 Oct 15;197:44-7. doi: 10.1016/j.ijcard.2015.06.020. Epub 2015 Jun 18. PMID: 26126053
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Diehl P, Bode C, Duerschmied D. Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. PMID: 26346960. Review.
Erin Morton (Other)
2015Activity: Other activity types › Other
-
Pancreatic Safety of Sitagliptin in the TECOS Study. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. PMID: 27630212. Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Am Heart J. 2016 Aug;178:176-84. doi: 10.1016/j.ahj.2016.05.012. Epub 2016 Jun 9. PMID: 27502866
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23. PMID: 26698636 Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P. Eur Heart J Acute Cardiovasc Care. 2017 Mar;6(2):155-163. doi: 10.1177/2048872616633880. Epub 2016 Sep 20. PMID: 26895973 Clinical Trial.
Erin Morton (Other)
2016Activity: Other activity types › Other
-
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD; STABILITY Investigators. J Am Coll Cardiol. 2017 Oct 3;70(14):1689-1700. doi: 10.1016/j.jacc.2017.08.017. PMID: 28958324 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077. PMID: 29066452. Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01. PMID: 28164012; PMCID: PMC5253449. H-index
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Guimarães PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, Lopes RD, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagström E, Danchin N. J Am Heart Assoc. 2017 Sep 14;6(9):e006695. doi: 10.1161/JAHA.117.006695. PMID: 28912210. Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6. PMID: 27607571 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6. PMID: 28986504
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7. PMID: 28432745 Clinical Trial.
Erin Morton (Other)
2017Activity: Other activity types › Other
-
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, MacPhee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D. PLoS One. 2017 Jul 28;12(7):e0182115. doi: 10.1371/journal.pone.0182115. eCollection 2017. PMID: 28753643.
Erin Morton (Other)
2017Activity: Other activity types › Other